Figure 6.

PF-03084014 combined with enzalutamide treatment induces a decrease in enzalutamide-resistant tumor xenograft. A and B, 22RV1 xenograft mice were treated with a vehicle control, enzalutamide, PF-03084014, or a combination of enzalutamide and PF-03084014 (PF). Upon completion, tumor weight and body weight were measured (n = 4 mice). C, representative image of tumors from different treatment groups. D, immunofluorescent images from tumor sections stained with cleaved Caspase-3, KI-67, AR, and 4′,6′-diamino-2-phenylindole (DAPI). E–G, quantification of cleaved Caspase-3, KI-67 and AR positively stained cells (n = 3). All groups were normalized to the vehicle control group. *, p [lt ]0.05; **, p < 0.01; ***, p < 0.001.